Orient Europharma (Taiwan) Performance
| 4120 Stock | TWD 42.00 0.20 0.47% |
Orient Europharma has a performance score of 10 on a scale of 0 to 100. The company holds a Beta of -0.0694, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Orient Europharma are expected to decrease at a much lower rate. During the bear market, Orient Europharma is likely to outperform the market. Orient Europharma right now holds a risk of 1.26%. Please check Orient Europharma downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to decide if Orient Europharma will be following its historical price patterns.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Orient Europharma Co are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Orient Europharma may actually be approaching a critical reversion point that can send shares even higher in June 2024. ...more
| Begin Period Cash Flow | 2.1 B | |
| Total Cashflows From Investing Activities | -1.5 B |
Orient |
Orient Europharma Relative Risk vs. Return Landscape
If you would invest 3,845 in Orient Europharma Co on February 1, 2024 and sell it today you would earn a total of 355.00 from holding Orient Europharma Co or generate 9.23% return on investment over 90 days. Orient Europharma Co is generating 0.1684% of daily returns and assumes 1.26% volatility on return distribution over the 90 days horizon. Simply put, 11% of stocks are less volatile than Orient, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Orient Europharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orient Europharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orient Europharma Co, and traders can use it to determine the average amount a Orient Europharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1337
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 4120 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.26 actual daily | 11 89% of assets are more volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Orient Europharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orient Europharma by adding it to a well-diversified portfolio.
Orient Europharma Fundamentals Growth
Orient Stock prices reflect investors' perceptions of the future prospects and financial health of Orient Europharma, and Orient Europharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orient Stock performance.
| Return On Equity | -0.0268 | |||
| Return On Asset | -0.0027 | |||
| Profit Margin | (0.02) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 5.9 B | |||
| Shares Outstanding | 86.75 M | |||
| Price To Book | 1.07 X | |||
| Price To Sales | 0.68 X | |||
| Revenue | 4.77 B | |||
| EBITDA | 313.89 M | |||
| Total Debt | 1.68 B | |||
| Book Value Per Share | 33.54 X | |||
| Cash Flow From Operations | 77.65 M | |||
| Earnings Per Share | 0.54 X | |||
| Total Asset | 9.4 B | |||
About Orient Europharma Performance
To evaluate Orient Europharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Orient Europharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Orient Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Orient Europharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Orient's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Things to note about Orient Europharma performance evaluation
Checking the ongoing alerts about Orient Europharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Orient Europharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orient Europharma has high likelihood to experience some financial distress in the next 2 years | |
| About 65.0% of the company shares are owned by insiders or employees |
- Analyzing Orient Europharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orient Europharma's stock is overvalued or undervalued compared to its peers.
- Examining Orient Europharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orient Europharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orient Europharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orient Europharma's stock. These opinions can provide insight into Orient Europharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Orient Europharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Orient Stock analysis
When running Orient Europharma's price analysis, check to measure Orient Europharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Europharma is operating at the current time. Most of Orient Europharma's value examination focuses on studying past and present price action to predict the probability of Orient Europharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Europharma's price. Additionally, you may evaluate how the addition of Orient Europharma to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |